Huntington disease

business targets illustration
Biotech

uniQure plans FDA push after Huntington's gene therapy trial win

The 36-month analysis showed a “statistically significant” 75% slowing of disease progression.
James Waldron Sep 24, 2025 9:20am
question unanswered wonder ask

PTC and Novartis’ Huntington's data fail to convince investors

May 6, 2025 7:25am
Graphic showing arrows missing the bullseye on a target

2024's top 10 clinical trial flops

Feb 18, 2025 3:00am
pay deal hand over cash licensing transaction money

Novartis pays PTC $1B upfront for midphase Huntington's program

Dec 2, 2024 7:53am
maze unravel find navigate direction path

uniQure's interim data shows gene therapy slows Huntington’s

Jul 9, 2024 9:25am
Visual of a brain

Sage's dalzanemdor trial design leaves efficacy question unclear

Jun 11, 2024 8:28am